Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neogen Corporation (NEOG) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Neogen’s operations in food safety, animal safety, and related markets, as well as its governance, compensation practices, and financial condition.
Neogen uses current reports on Form 8-K to disclose material events such as the appointment of a new President and Chief Executive Officer, changes in the Chief Financial Officer role, director retirements and appointments, and the results of shareholder votes at its annual meeting. Filings describe executive compensation arrangements, including base salary, annual bonus targets, long-term equity incentives, and performance share unit programs tied to metrics like revenue growth, adjusted EBITDA margin expansion, and cash flow conversion.
Investors can also review 8-K filings that furnish earnings press releases, which summarize quarterly and annual results, segment performance for Food Safety and Animal Safety, and non-GAAP measures such as adjusted EBITDA. These filings complement the company’s financial statements by providing narrative context and reconciliations.
On Stock Titan, NEOG filings are updated as they are posted to EDGAR, and AI-powered summaries can help explain key elements of lengthy documents, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Users can quickly identify disclosures related to executive and director changes, incentive plans, shareholder meeting outcomes, and other governance matters.
This page is a resource for understanding how Neogen describes its strategy, risk factors, performance metrics, and capital structure in its own words through formal SEC filings, with tools to make complex regulatory content more accessible.
NEOGEN CORP CEO Nassif Mikheal filed an amended Form 3 reporting indirect holdings of company common shares held by his son. The amendment lists two indirect positions of 318 and 302 common shares as of August 11, 2025. A footnote states that Mikheal disclaims beneficial ownership of these securities, meaning he does not acknowledge them as his own holdings for Section 16 or other purposes.
Neogen (NEOG) reported an insider equity transaction by its CFO. On 11/03/2025, the officer acquired 178,855 shares of common stock at a stated price of $6.29, bringing directly held common shares to 178,855. The filing also shows a grant of stock options for 459,713 shares with an exercise price of $6.29.
According to the footnotes, the options vest in equal annual installments over three years from the grant date, while the performance stock units vest in total at the end of the three-year anniversary of the grant.
NEOGEN Corp (NEOG) reported an initial beneficial ownership filing for its Chief Financial Officer on Form 3. The filing states the officer is an Officer (Chief Financial Officer) and that the form was filed by one reporting person.
No securities are beneficially owned, according to the “Explanation of Responses.” The event requiring the statement occurred on 11/03/2025.
Neogen Corporation appointed Bryan Riggsbee as Senior Vice President and Chief Financial Officer, effective November 3, 2025, reporting to President and CEO Mike Nassif. Riggsbee previously served as CFO, North America at bioMérieux and spent nearly a decade as CFO at Myriad Genetics, with earlier finance roles at LabCorp, GE, and KPMG.
His compensation includes a $600,000 base salary, target annual bonus at 80% of salary under the ICP, and an annual long‑term equity grant targeted at $2,000,000. He will receive a one‑time equity inducement of $2,250,000 (50% stock options vesting ratably over three years and 50% PSUs aligned with the FY26 PSU Plan) and a $250,000 cash sign‑on payable by December 31, 2025, subject to repayment if employment ends within one year. He will relocate to Michigan within 24 months with customary relocation benefits and applicable repayment provisions.
Neogen Corp (NEOG) reported a director’s equity transaction. On 10/27/2025, 1,777 restricted stock units (RSUs) vested and were settled into an equal number of common shares via transaction code M. The non-derivative table shows 1,777 shares acquired at a listed price of $6.19. Following the transaction, the reporting person beneficially owned 96,347 shares directly. Remarks confirm each RSU equals one share and that the RSUs vested and were settled on the same date.
NEOGEN Corp (NEOG) insider update: A company director reported the vesting and settlement of 1,777 restricted stock units into an equal number of common shares on 10/27/2025. The filing lists a reported price of $6.19 for the transaction. Following this event, the director directly beneficially owns 32,502 shares of NEOG common stock.
Neogen Corporation reported an insider transaction on Form 4 for a director. On 10/27/2025, 1,777 shares of common stock were acquired upon settlement of restricted stock units (Transaction Code: M) at a stated price of $6.19 per share. Following the transaction, the director beneficially owned 18,654 shares, held directly.
The filing notes each RSU equals one share of common stock and that these RSUs vested and were settled on 10/27/2025.
Neogen Corporation (NEOG) reported an insider equity change. A director acquired 1,777 shares of common stock on October 27, 2025 through the vesting and settlement of restricted stock units (transaction code M), listed at $6.19 per share. Following this transaction, the director’s beneficial ownership stands at 27,790 shares, held directly.
Each RSU converted into one share of common stock at vesting, resulting in a one-for-one issuance without a market purchase.
Neogen Corporation (NEOG) reported an insider equity change. A director acquired 1,777 shares of common stock on 10/27/2025 upon the settlement of restricted stock units, recorded at $6.19 per share under code M. Following the transaction, the director directly beneficially owned 20,821 shares.
Each RSU was the economic equivalent of one common share and vested on 10/27/2025, settling into an equal number of shares of common stock.
NEOGEN (NEOG) reported a routine insider equity event. A director acquired 1,777 shares of common stock on 10/27/2025 through the vesting and settlement of restricted stock units, reflected with transaction code M. The filing lists a price of $6.19 associated with the conversion. Following this transaction, the director beneficially owns 43,347 shares, held directly.